Barbara Weber - Mar 1, 2023 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Chief Executive Officer, Director
Signature
/s/ Douglas Barry, attorney-in-fact
Stock symbol
TNGX
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
3/2/2023, 03:06 PM
Previous filing
Jun 17, 2022
Next filing
Jun 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Award $0 +89.5K +6.55% $0.00 1.46M Mar 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +537K $0.00 537K Mar 1, 2023 Common Stock 537K $5.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2 This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.